Weekly rifapentine/isoniazid or daily rifampin/pyrazinamide for latent tuberculosis in household contacts (Q24650581)

8

object named as

Richard E Chaisson

0 references

author name string

Roberto Zajdenverg

2

0 references

Gisely Falco

3

0 references

Grace Link Barnes

4

0 references

José Cláudio Faulhaber

5

0 references

Jacqueline S Coberly

6

0 references

Richard D Moore

American Journal of Respiratory and Critical Care Medicine

7

0 references

language of work or name

English

0 references

publication date

15 April 2006

0 references

published in

0 references

volume

173

0 references

issue

8

0 references

page(s)

922-6

0 references

cites work

Targeted tuberculin testing and treatment of latent tuberculosis infection. American Thoracic Society

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2662911

Analysis of rifapentine for preventive therapy in the Cornell mouse model of latent tuberculosis

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2662911

Epidemiology of hepatitis A and E virus infection in Brazil

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2662911

Update: adverse event data and revised American Thoracic Society/CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection--United States, 2003.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2662911

Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a multicenter clinical trial.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2662911

Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2662911

Controlled chemoprophylaxis trials in tuberculosis. A general review

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2662911

Short-course chemoprophylaxis for tuberculosis

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2662911

Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2662911

Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. Terry Beirn Community Programs for Clinical Research on AIDS, the Adult AIDS Clinical Trials Group, the Pan American He

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2662911

Twice weekly tuberculosis preventive therapy in HIV infection in Zambia

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2662911

Effectiveness of rifampin, rifabutin, and rifapentine for preventive therapy of tuberculosis in mice

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2662911

Pulmonary hypertension and right heart failure in chronic obstructive pulmonary disease

30 May 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200512-1953OC

Pharmacokinetics of rifapentine at 600, 900, and 1,200 mg during once-weekly tuberculosis therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200512-1953OC

Transmission of tuberculosis to close contacts of patients with multidrug-resistant tuberculosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200512-1953OC

Short-course rifamycin and pyrazinamide treatment for latent tuberculosis infection in patients with HIV infection: the 2-year experience of a comprehensive community-based program in Broward County, Florida

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200512-1953OC

Safety of 2 months of rifampin and pyrazinamide for treatment of latent tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200512-1953OC

Pyrazinamide and rifampin vs isoniazid for the treatment of latent tuberculosis: improved completion rates but more hepatotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200512-1953OC

Hepatotoxicity of rifampin and pyrazinamide in the treatment of latent tuberculosis infection in HIV-infected persons: is it different than in HIV-uninfected persons?

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200512-1953OC

Hepatotoxicity of rifampin-pyrazinamide and isoniazid preventive therapy and tuberculosis treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200512-1953OC

Cost-effectiveness of isoniazid chemoprevention in close contacts

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200512-1953OC

Treatment completion and costs of a randomized trial of rifampin for 4 months versus isoniazid for 9 months

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200512-1953OC

Randomised trial of isoniazid versus rifampicin and pyrazinamide for prevention of tuberculosis in HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200512-1953OC

Is the combination of pyrazinamide plus rifampicin safe for treating latent tuberculosis infection in persons not infected by the human immunodeficiency virus?

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2662911

Update: Fatal and severe liver injuries associated with rifampin and pyrazinamide treatment for latent tuberculosis infection.

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2662911

Seroepidemiological markers of enterically transmitted viral hepatitis A and E in individuals living in a community located in the North Area of Rio de Janeiro, RJ, Brazil

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2662911

Update: Fatal and severe liver injuries associated with rifampin and pyrazinamide for latent tuberculosis infection, and revisions in American Thoracic Society/CDC recommendations--United States, 2001.

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2662911

Preventive therapy of tuberculosis with rifapentine in immunocompetent and nude mice

28 November 2018

1 reference

12 December 2020

Rifapentine and isoniazid in the continuation phase of treating pulmonary tuberculosis. Initial report

1 reference

12 December 2020

Contact examination for tuberculosis in Hong Kong is useful

1 reference

12 December 2020

A double-blind placebo-controlled clinical trial of three antituberculosis chemoprophylaxis regimens in patients with silicosis in Hong Kong. Hong Kong Chest Service/Tuberculosis Research Centre, Madras/British Medical Research Council

1 reference

12 December 2020